These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Balbuena-Merle R, Hendrickson JE. Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806 [Abstract] [Full Text] [Related]
7. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature. Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW. Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787 [Abstract] [Full Text] [Related]
8. Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature. Jasinski S, Glasser CL. J Pediatr Hematol Oncol; 2019 Nov; 41(8):624-626. PubMed ID: 30179992 [Abstract] [Full Text] [Related]
9. Effects of prophylactic red blood cell (RBC) transfusion with extended antigen matching on alloimmunization in patients with Sickle Cell Disease (SCD). Leal I, Dos Santos TD, Gilli S, Castilho L. Transfus Apher Sci; 2023 Dec; 62(6):103813. PubMed ID: 37743224 [Abstract] [Full Text] [Related]
10. Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients. Dean CL, Maier CL, Chonat S, Chang A, Carden MA, El Rassi F, McLemore ML, Stowell SR, Fasano RM. Transfusion; 2019 May; 59(5):1698-1705. PubMed ID: 30848512 [Abstract] [Full Text] [Related]